Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVENT: SNG001 for Respiratory Virus Infection Requiring Mechanical Ventilation
NCT06999603Phase 2Terminated
- Sponsor
- Synairgen
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, randomised trial of interferon beta-1a in viral pneumonia (4 arms), sponsored by Synairgen. Primary endpoints: Adverse Events and Serious Adverse Events Severity at 42 days and All-cause Mortality at 28 days. Started Sep 2025; status: terminated.
02
Drugs
interferon beta-1a
03
Conditions
viral pneumonia
Beyond the preview
Go deeper on NCT06999603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999603.